Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma

International Journal of Hematology

Volumn 84, Issue 3, 2006, Pages 242-247

  Fukuno, Kenji ^a,b   Tsurumi, Hisashi ^b   Ando, Nobuhiro ^a   Kanemura, Nobuhiro ^a   Goto, Hideko ^a   Tanabashi, Shinobu ^a   Okamoto, Kiyonao ^a   Moriwaki, Hisataka ^b  

^a Takayama Red Cross Hospital   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Late onset; Neutropenia; Non Hodgkin's lymphoma; Rituximab; Stromal derived factor 1

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CD20 ANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3D; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD TOXICITY; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CELL MATURATION; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; NEUTROPHILS; TIME FACTORS;

EID: 33750378796     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05105     Document Type: Article

References (20)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
2. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932.
3. Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999;17:1851-1857.
4. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999;10:655-666.
5. Tsai D, Moore H, Hardy C, et al. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Bone Marrow Transplant. 1999;24:521-526.
6. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135-3143.
7. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324.
8. Igarashi T, Ohtsu T, Fujii H, et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol. 2001;73:213-221.
9. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101-106.
10. Tobinai K. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. Int J Hematol. 2002;76:411-419.
11. Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:4261-4267.
12. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003;121:913-918.
13. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med. 2003;348:2691-2694.
14. Papadaki T, Stamatopoulos K, Stavroyianni N, Paterakis G, Phisphis M, Stefanoudaki-Sofianatou, K. Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases. Leuk Res. 2002;26:597-600.
15. Flinn IW, O'Donnell PV, Goodrich A, Vogelsang G, Abrams R, Noga S. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2000;6:628-632.
16. Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. 2004;33:921-923.
17. Dunleavy K, Hakim F, Kim HK, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005;106:795-802.
18. Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382:635-638.
19. Martin C, Burdon PC, Bridger G, Gutierrez-Ramos JC, Williams TJ, Rankin SM. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity. 2003;19:583-593.
20. + T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felly's and large granular lymphocyte syndromes. Arthritis Rheum. 2000;43:834-843.